Impact of Ursodeoxycholic Acid Capsules Combined with Glucocorticoids on Liver Fibrosis Indicators and Immune Function in Patients with Autoimmune Hepatitis
Objective To analyze the impact of ursodeoxycholic acid capsules combined with glucocorticoids on liver fibrosis and immune function in patients with autoimmune hepatitis(AIH).Methods 84 AIH patients admitted to our hospital from January 2022 to January 2023 were selected and randomly divided into two groups,with 42 cases in each group.The control group was treated with glucocorticoids,and the observation group was treated with ursodeoxycholic acid capsules.Both groups were treated for 6 months.The clinical effect,liver fibrosis indicators,immune function and adverse reactions were compared between the two groups.Results The total effective rate of treatment in the observation group was higher than that in the control group(P＜0.05).After treatment,the liver fibrosis indicators and immune function indicators of the observation group were lower than those of the control group(P＜0.05).No obvious adverse reactions was found in the two groups during treatment.Conclusions Ursodeoxycholic acid capsules combined with glucocorticoids has significant effect in the treatment of AIH patients,which can improve the liver fibrosis indicators,promote the recovery of liver function,and enhance the immune function,with higher safety in clinical application.
Autoimmune hepatitisUrsodeoxycholic acid capsuleGlucocorticoidsLiver fibrosisImmune function
国家科技期刊平台
NSTL
万方数据
